REG - Scancell Hlds - Issue of share options to Non-Executive Directors

Scancell HoldingsAnnouncement

21/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230421:nRSU9791Wa&default-theme=true

RNS Number : 9791W  Scancell Holdings Plc  21 April 2023

21 April 2023

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Issue of share options to Non-Executive Directors

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, announces that on 20 April
2023 it has granted share options to acquire ordinary shares of 0.1 pence each
in the capital of the Company to the following non-executive directors:

 

                   Dr Jean-Michel
Cosséry                 3,000,000

                   Susan Clement
Davies                  1,000,000

 

These share options have an exercise price of 17.5 pence each, the closing
share price as at 19 April 2023, and will vest over three years in three equal
tranches from 20 April 2023 with no vesting criteria other than to remain in
employment. Any unexercised share options which are being granted per the
above will expire at 6pm on 20 April 2033.

 

The Board of Scancell approved the issuance of these share option grants to
incentivise and retain Directors of the Company. The Board considered both
historical practices and on-going funding requirements in this regard.

 

Related Party Transaction

 

The issue of share options to Dr. Jean-Michel Cosséry and Susan Clement
Davies are deemed to be related party transactions pursuant to AIM Rule 13 of
the AIM Rules for Companies. The Company's directors who are independent of
the related party transactions (being all the directors other than Dr.
Jean-Michel Cosséry and Susan Clement Davies) consider, having consulted with
the Company's Nominated Adviser, Stifel Nicolaus Europe Limited, that the
terms of the related party transactions are fair and reasonable insofar as the
shareholders of the Company are concerned.

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

  1   Details of the person discharging managerial responsibilities/person closely
      associated
 a)   Name                                                         Jean-Michel Cosséry
 2    Reason for the notification
 a)   Position/status                                              Chairman of Board and PDMR
 b)   Initial notification/Amendment                               Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         Scancell Holdings plc
 b)   LEI                                                          2138008RXEG856SNP666
 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Options to acquire ordinary shares
 b)   Identification Code                                          GB00B63D3314
 c)   Nature of the transaction                                    Grant of options to acquire ordinary shares

 d)   Price(s) and volume(s)                                       3,000,000 share options

                                                                   17.5 pence per share option
 e)   Aggregated information

      - Aggregated volume                                          N/A (single transaction)

      - Price
 f)   Date of the transaction                                      20 April 2023
 g)   Place of the transaction                                     Outside a trading venue

 

  1   Details of the person discharging managerial responsibilities/person closely
      associated
 a)   Name                                                         Susan Clement Davies
 2    Reason for the notification
 a)   Position/status                                              Non- Executive Director and PDMR
 b)   Initial notification/Amendment                               Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         Scancell Holdings plc
 b)   LEI                                                          2138008RXEG856SNP666
 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Options to acquire ordinary shares
 b)   Identification Code                                          GB00B63D3314
 c)   Nature of the transaction                                    Grant of options to acquire ordinary shares

 d)   Price(s) and volume(s)                                       1,000,000 share options

                                                                   17.5 pence per share option
 e)   Aggregated information

      - Aggregated volume                                          N/A (single transaction)

      - Price
 f)   Date of the transaction                                      20 April 2023
 g)   Place of the transaction                                     Outside a trading venue

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 (MAR)

 

 For further information, please contact:

 Scancell Holdings plc                                                        +44 (0) 20 3727 1000
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment
 Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 Panmure Gordon (UK) Limited (Joint Broker)                                   +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 FTI Consulting                                                               +44 (0) 20 3727 1000
 Simon Conway/Rob Winder/Alex Davis

 

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHNKKBNOBKDDQB